Skip to search formSkip to main contentSkip to account menu

AMG623 peptibody

Known as: A-623 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Background Blisibimod (A-623, AMG 623), a potent and selective inhibitor of B-cell activating factor (BAFF), was evaluated in the… 
Review
2012
Review
2012
For the first time in more than 50 years, the US Food and Drug Administration has approved a drug specifically for the treatment… 
2012
2012
OBJECTIVES AMG623, also known as A-623, is an antagonist of B-cell activating factor (BAFF). The present study was to evaluate… 
2006
2006
There were no significant differences in MAP, HR, SpO2 and BIS between the three groups. Incidence of side-effects was… 
2005
2005
Department of Anaesthesiology, University Hospital Aachen, Aachen, Germany Background and Aim of Study: In head injured patients…